FDA expands treatment options with three new ophthalmic approvals for ocular redness, thyroid eye disease, and presbyopia

The U.S. Food and Drug Administration (FDA) has approved three new ophthalmic treatments. These include Alcon's apraclonidine ophthalmic solution 0.125% (Brytly), marking the first nonprescription eye drop for ocular redness due to minor irritations. Additionally, Genentech's Enspryng (satralizumab-mwge) received approval as the first at-home subcutaneous therapy for thyroid eye disease (TED). Lastly, Opus Genetics' phentolamine ophthalmic solution, 0.75% (RYZUMVI), was approved for the treatment of presbyopia.